Time to buy?-To The Moon - Tiger Brokers Online Investing Community - To The Moon

1
Comment
Favorite

druvaciam
01-02

Time to buy?

Corcept Therapeutics Plunges 33% After Loss in Patent Battle With With Teva

Corcept Therapeutics plummeted 30.5% in premarket trading Tuesday after a loss in a patent trial with Teva Pharmaceuticals over a patent for Cushing’s syndrome drug Korlym.The court found that Corcept hadn't met its burden of proving induced infringement, according to a court ruling late Friday by Judge Renée Marie Bumb of the US District Court for the District of New Jersey."ORDERED that Teva has not infringed, and that Teva’s making, using, offering to sell, selling, or importing Teva’s gener

Corcept Therapeutics Plunges 33% After Loss in Patent Battle With With Teva

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":258714111918136,"tweetId":"258714111918136","gmtCreate":1704196658887,"gmtModify":1704196663437,"author":{"id":4088707402306530,"authorId":4088707402306530,"authorIdStr":"4088707402306530","name":"druvaciam","avatar":"https://static.tigerbbs.com/5c3fb456a34258529f2ed7b7f945e0e8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Time to buy?</p></body></html>","htmlText":"<html><head></head><body><p>Time to buy?</p></body></html>","text":"Time to buy?","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/258714111918136","repostId":1170584568,"repostType":2,"repost":{"id":"1170584568","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1704195354,"share":"https://www.laohu8.com/m/news/1170584568?lang=&edition=full","pubTime":"2024-01-02 19:35","market":"us","language":"en","title":"Corcept Therapeutics Plunges 33% After Loss in Patent Battle With With Teva","url":"https://stock-news.laohu8.com/highlight/detail?id=1170584568","media":"Tiger Newspress","summary":"Corcept Therapeutics plummeted 30.5% in premarket trading Tuesday after a loss in a patent trial with Teva Pharmaceuticals over a patent for Cushing’s syndrome drug Korlym.The court found that Corcept  hadn't met its burden of proving induced infringement, according to a court ruling late Friday by Judge Renée Marie Bumb of the US District Court for the District of New Jersey.\"ORDERED that Teva has not infringed, and that Teva’s making, using, offering to sell, selling, or importing Teva’s gener","content":"<html><head></head><body><p>Corcept Therapeutics plummeted 32.6% in premarket trading Tuesday after a loss in a patent trial with Teva Pharmaceuticals over a patent for Cushing’s syndrome drug Korlym.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/075383dabb3c465c0e201b07a41b7229\" tg-width=\"844\" tg-height=\"616\"/></p><p style=\"text-align: left;\">The court found that Corcept (CORT) hadn&#39;t met its burden of proving induced infringement, according to a court ruling late Friday by Judge Renée Marie Bumb of the US District Court for the District of New Jersey.</p><p style=\"text-align: left;\">&#34;ORDERED that Teva has not infringed, and that Teva’s making, using, offering to sell, selling, or importing Teva’s generic mifepristone product will not infringe, claims 10–13 of the ʼ214 Patent or claims 1, 6, 7, and 9 of the ’800 Patent,&#34; the judge wrote in the opinion on Friday.</p><p style=\"text-align: left;\">The court ruling comes after a trial in late September, which sent Corcept (CORT) shares plunging 17% on Sept. 17.</p><p style=\"text-align: left;\">Corcept (CORT) has been in a patent battle with Teva (TEVA) over a patent for Cushing’s syndrome drug Korlym, marketed by Corcept. In December 2021 Teva lost an attempt to invalidate a parent for Korlym.</p><p style=\"text-align: left;\">Corcept (CORT) originally sued Teva (TEVA) in federal court in March 2018 to prevent it from marketing a generic version of Korlym.</p><p style=\"text-align: left;\">Corcept&#39;s (CORT) short interest is 18%.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept Therapeutics Plunges 33% After Loss in Patent Battle With With Teva</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept Therapeutics Plunges 33% After Loss in Patent Battle With With Teva\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2024-01-02 19:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Corcept Therapeutics plummeted 32.6% in premarket trading Tuesday after a loss in a patent trial with Teva Pharmaceuticals over a patent for Cushing’s syndrome drug Korlym.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/075383dabb3c465c0e201b07a41b7229\" tg-width=\"844\" tg-height=\"616\"/></p><p style=\"text-align: left;\">The court found that Corcept (CORT) hadn&#39;t met its burden of proving induced infringement, according to a court ruling late Friday by Judge Renée Marie Bumb of the US District Court for the District of New Jersey.</p><p style=\"text-align: left;\">&#34;ORDERED that Teva has not infringed, and that Teva’s making, using, offering to sell, selling, or importing Teva’s generic mifepristone product will not infringe, claims 10–13 of the ʼ214 Patent or claims 1, 6, 7, and 9 of the ’800 Patent,&#34; the judge wrote in the opinion on Friday.</p><p style=\"text-align: left;\">The court ruling comes after a trial in late September, which sent Corcept (CORT) shares plunging 17% on Sept. 17.</p><p style=\"text-align: left;\">Corcept (CORT) has been in a patent battle with Teva (TEVA) over a patent for Cushing’s syndrome drug Korlym, marketed by Corcept. In December 2021 Teva lost an attempt to invalidate a parent for Korlym.</p><p style=\"text-align: left;\">Corcept (CORT) originally sued Teva (TEVA) in federal court in March 2018 to prevent it from marketing a generic version of Korlym.</p><p style=\"text-align: left;\">Corcept&#39;s (CORT) short interest is 18%.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CORT":"Corcept医疗","TEVA":"梯瓦制药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170584568","content_text":"Corcept Therapeutics plummeted 32.6% in premarket trading Tuesday after a loss in a patent trial with Teva Pharmaceuticals over a patent for Cushing’s syndrome drug Korlym.The court found that Corcept (CORT) hadn't met its burden of proving induced infringement, according to a court ruling late Friday by Judge Renée Marie Bumb of the US District Court for the District of New Jersey.\"ORDERED that Teva has not infringed, and that Teva’s making, using, offering to sell, selling, or importing Teva’s generic mifepristone product will not infringe, claims 10–13 of the ʼ214 Patent or claims 1, 6, 7, and 9 of the ’800 Patent,\" the judge wrote in the opinion on Friday.The court ruling comes after a trial in late September, which sent Corcept (CORT) shares plunging 17% on Sept. 17.Corcept (CORT) has been in a patent battle with Teva (TEVA) over a patent for Cushing’s syndrome drug Korlym, marketed by Corcept. In December 2021 Teva lost an attempt to invalidate a parent for Korlym.Corcept (CORT) originally sued Teva (TEVA) in federal court in March 2018 to prevent it from marketing a generic version of Korlym.Corcept's (CORT) short interest is 18%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":130,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":10,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}